FTC orders Mylan to divest two generics

09-09-2016

The US Federal Trade Commission (FTC) announced yesterday that it has approved a final order in Mylan’s $7.2 billion acquisition of Meda, a Swedish drug maker, deciding that the activity would be anticompetitive.


Mylan, Meda, FTC, anticompetitive, carisoprodol, felbamate

LSIPR